On July 8, 2021, Ovid Therapeutics Inc. filed the Original Filing disclosing that the Company’s Board of Directors had appointed Dr. Robert Michael Poole as a director of the Company effective July 9, 2021. At the time of filing of the Original 8-K, the Board had not determined the committee assignments for Dr. Poole. This Amendment Filing is being filed to report that on August 5, 2021, the Board appointed Dr. Poole to serve as a member of each of the Audit Committee of the Board and the Compensation Committee of the Board. As of August 5, 2021, the Audit Committee of the Board consists of Barbara Duncan, as Chair, Karen Bernstein, Bart Friedman and Dr. Poole; the Compensation Committee of the Board consists of Ms. Bernstein, as Chair, Mr. Friedman and Dr. Poole; and the Nominating & Corporate Governance Committee of the Board consists of Ms. Bernstein, as Chair, Mr. Friedman and Ms. Duncan.